News

London, UK, September 26, 2022 – Cyberliver Ltd., a digital health company focusing on delivering cutting edge solutions for liver care, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to the company’s CirrhoCare device for out-of-hospital, specialist hepatology management of cirrhosis patients, who are at risk of new acute complications of cirrhosis (decompensation events).

During the current COVID-19 pandemic, patients with cirrhosis have limited access to direct clinical review, and many avoid hospital for fear of infection. Invariably this has meant that many cirrhosis patients will not receive the level of care they need and will incur further morbidity and mortality. Innovate UK is initiating a CirrhoCare project to address this clinical need through remote digital monitoring of at-risk cirrhosis patients, thereby improving the clinical workflow and patient outcomes

CyberLiver has been recommended by the NIHR Invention for Innovation Programme for funding to support a real-world implementation of AlcoChange, a Digital Therapeutic to improve outcomes from Alcohol-Related Liver Disease. A full-scale Randomised Controlled Trial of AlcoChange will take place across 18 centres in the UK

Cyberliver reports a positive pilot study of AlcoChange, a patented Smartphone Tool and Behavioural Intervention Platform to Reduce Alcohol Consumption in Alcohol-Related Liver Disease. The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life. Cyberliver Ltd., a developer of cutting edge solutions for liver care, today announced that Dr Gautam Mehta and team will present a poster at The Liver Meeting 2018 of the American Association for the Study of Liver Diseases

Alcohol contributes to over 5% of deaths worldwide, and death rates from alcohol-related liver disease (ARLD) in the UK continue to rise sharply. On-going alcohol use in ARLD leads to markedly increased mortality (Thursz et al, 2015), and maintaining abstinence is a key therapeutic goal. A 15-month Pilot Study into the use of AlcoChange to reduce alcohol use and admissions in alcoholic liver disease has just completed, with very positive results showing a 63% reduction in alcohol use amongst compliant participants